None listed
Conditions
Interventions
None listed
Sponsors
Celltrion Pharm
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 19 ~70 years old (Adult over 19 under the age of 70) 2. Subjects who were diagnosed with NAFLD 3. If treated group, subjects who were treated with carnitine complex (824mg PO, TID) for at least 24 weeks form index date 4. If control group, subjects who were not taking hepatotonic medications at least 24 weeks from index dates
Exclusion criteria
Exclusion criteria: 1. Chronic alcoholic disease 2. Acute hepatitis A, Viral liver disease, drug induced liver disease, biliary obstruction (Chronic hepatitis B patients without taking antiviral agent are eligible) 3. Subjects who administered oral hypoglycemic agent including insulin. 4. Subjects who administered hyperlipidemia medication, antiobestic medication 5. Subjects who administered hepatotonics except for carnitine complex (Godex cap.) 6. Subjects with progressive diseases such as malignant tumor 7. Subjects accompanying active hemorrhage 8. Other subjects who are not eligible for this study
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| The changes in ALT, AST level;The decline of liver steatosis in liver ultrasonography;Correlation between changes in Fibroscan CAP values and ALT, AST levels;Correlation between changes in Fibroscan CAP values and blood glucose levels;Correlation between changes in Fibroscan CAP values and lipid parameters;The changes of Hepatic Steatosis Index (HSI);The changes of glycemic control (HbA1c, fasting glucose, fasting insulin);Safety evaluation | — |
Primary
| Measure | Time frame |
|---|---|
| The decline in Fibroscan CAP values | — |
Countries
Korea, Republic of
Contacts
Public ContactYongkyun Cho
Kangbuk Samsung Medical Center
Outcome results
None listed